OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cohen on Diversifying the Patient Population for a Clinical Trial in Medullary Thyroid Cancer

April 19th 2022

Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).

Dr Cabanillas on Delivering the "Right" Surgery to Patients With MTC

April 19th 2022

Maria E. Cabanillas, MD, an oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses how to deliver the optimal surgical approach to patients with medullary thyroid cancer.

Dr. Choueiri on Next Steps for Pembrolizumab in RCC

April 19th 2022

Toni Choueiri, MD, discusses the next steps for the evaluation of pembrolizumab in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma.

Dr Cabanillas on Current Systemic Treatments in MTC and the Potential for PRRT

April 19th 2022

Maria E. Cabanillas, MD, oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses current systemic treatments in medullary thyroid cancer, along with the potential for peptide receptor radionuclide therapy.

Dr. Oberstein on the Utilization of CtDNA in Metastatic CRC

April 18th 2022

Paul E. Oberstein, MD, discusses the utilization of ctDNA in metastatic colorectal cancer.

Dr. Tawbi on the Utilization of Relatlimab and Nivolumab in Metastatic Melanoma

April 18th 2022

Hussein A. Tawbi, MD, PhD, discusses the utilization of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Dr. Ornstein on the Efficacy of Neoadjuvant Avelumab and Axitinib in RCC

April 18th 2022

Moshe Ornstein, MD, MA, discusses the efficacy findings from a phase 2 trial examining neoadjuvant avelumab and axitinib in renal cell carcinoma.

Dr. Pollyea on the Role of Maintenance Therapy in AML

April 14th 2022

Dan Pollyea, MD, MS, discusses the current role of maintenance therapy in patients with acute myeloid leukemia who are unfit for intensive chemotherapy.

Dr. Carraway on Next-Generation Sequencing in AML

April 14th 2022

Hetty Carraway, MD, discusses important considerations for the future of acute myeloid leukemia regarding mutations and next-generation sequencing.

Dr. Maron on HER2-Positive Tumors in Esophageal Gastric Cancers

April 14th 2022

Steven Maron, MD, MSc, discusses HER2-positive tumors in esophageal gastric cancers.

Dr. Rivero on Monocytic Differentiation in AML

April 14th 2022

Gustavo Rivero, MD, discusses evolving therapies for patients with acute myeloid leukemia with monocytic differentiation.

Dr. Hong on Comparing the Use of Sotorasib and Adagrasib in CRC

April 14th 2022

David S. Hong, MD, discusses data examining the use of sotorasib (Lumakras) and adagrasib in colorectal cancer.

Dr. Moon on the Role of PARP Inhibitors in Prostate Cancer

April 14th 2022

Helen Heng-Shan Moon, MD, discusses the role of PARP inhibitors in prostate cancer.

Dr. Oberstein on the Current Treatment Landscape of CRC

April 13th 2022

Paul E. Oberstein, MD, discusses the current treatment landscape of colorectal cancer.

Dr. Ornstein on the Benefit of Neoadjuvant Therapy in RCC

April 13th 2022

Moshe Ornstein, MD, MA, discusses the benefit of neoadjuvant therapy in renal cell carcinoma.

Dr. Iacovelli on Eligibility Criteria of the ARIES Trial in Urothelial Cancer

April 13th 2022

Roberto Iacovelli, MD, PhD, discusses the patient eligibility criteria of the phase 2 ARIES trial in urothelial cancer.

Dr. Moon on the FDA Approval of Relatlimab Plus Nivolumab in Metastatic Melanoma

April 13th 2022

Helen Heng-Shan Moon, MD, discusses the FDA approval of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

Dr. Edington on the Evolving Treatment Paradigm of Melanoma

April 12th 2022

Howard D. Edington, MD, discusses the evolving treatment paradigm of melanoma.

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

April 12th 2022

Martin Dietrich, MD, PhD, discusses optimizing treatment options for patients with mantle cell lymphoma.

Dr. Jeyarajah on Aggressive Treatment while Preserving Quality of Life in CRC

April 12th 2022

Rohan Jeyarajah, MD, discusses aggressive treatment while preserving quality of life in patients with colorectal cancer.